Myeloma(Cell BT)(Myeloma(Cell BT)) - 在研适应症：淀粉样变性多发性神经炎_专利_临床

概要

基本信息

药物类型

CAR-T

别名-

靶点-

作用方式-

作用机制-

治疗领域

神经系统疾病

在研适应症

淀粉样变性多发性神经炎

非在研适应症-

原研机构

Cell BT

在研机构

Precision BioSciences, Inc.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Myeloma(Cell BT) 相关的临床结果

登录后查看更多信息

100 项与 Myeloma(Cell BT) 相关的转化医学

登录后查看更多信息

100 项与 Myeloma(Cell BT) 相关的专利（医药）

登录后查看更多信息

1

项与 Myeloma(Cell BT) 相关的文献（医药）

2014-12-01·Haematologica

Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials

作者: Mailankody, Sham ; Landgren, Ola ; Manasanch, Elisabet E ; Roschewski, Mark ; Bhutani, Manisha ; Tageja, Nishant ; Korde, Neha

5A recent randomized phase III clinical trial reported a prolongation in progressionfree survival (PFS) and overall survival (OS) with early treat ment of patients with high-risk smoldering multiple myeloma (SMM). 6 Typically, these patients are diagnosed incidentally on routine evaluations and have no end-organ damage. 7 Given that a key aspect of clinical medicine is “first, do no harm”, a dilemma exists regarding early intervention for SMM. Clinical trials in medicine are systematic investigations to develop generalizable knowledge. In the field of multiple myeloma, unanswered fundamental questions need to be addressed through clinical trials. Is earlier treatment in myelo ma adequate? When should treatment be initiated? What pop ulation is the most likely to benefit? What treatment strategy should we use? What type of disease monitoring after initial therapy should we employ?

100 项与 Myeloma(Cell BT) 相关的药物交易

登录后查看更多信息